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Abstract 
E. coli CoaBC, part of the vital coenzyme A biosynthetic pathway in bacteria, has recently been 
validated as a promising antimicrobial target. In this work, we employed native ion mobility-
mass spectrometry to gain structural insights into the phosphopantothenoylcysteine synthetase 
domain of CoaBC. Moreover, native mass spectrometry was validated as a screening tool to 
identify novel inhibitors of this enzyme, highlighting the utility and versatility of this technique 
both for structural biology and for drug discovery. 
Introduction 
Coenzyme A (CoA) is a ubiquitous and essential cofactor that is synthesized from 




 In the second step, phosphopantothenoylcysteine synthetase (PPCS) catalyzes 
the Mg
2+
-dependent conversion of 4′-phosphopantothenate (PPan) and L-cysteine into 4′-
phosphopantothenoylcysteine (PPC) using either CTP (in bacteria) or ATP (in eukaryotes) for 
activation.
2
 In bacteria, PPan is first coupled with the α-phosphate of CTP to give an acyl 
cytidylate intermediate, 4′-phosphopantothenoyl cytidylate, with the concomitant release of 
pyrophosphate (PPi) (Figure 1a). The CMP-activated acyl group is then transferred to the amino 
group of L-cysteine, and PPC and CMP are released.
2
 
Bacterial PPCS, also referred to as CoaB, is typically fused to the next enzyme of the CoA 
biosynthetic pathway, phosphopantothenoylcysteine decarboxylase (PPCDC, also referred to as 
CoaC in bacteria) to form the bifunctional CoaBC protein (coaBC gene product, previously 
known as dfp).
3
 The bacterial CoaBC enzyme has been proposed to be a dodecamer based on gel 
filtration experiments
4
 and by analogy with the related flavoprotein EpiD, for which the X-ray 
crystal structure has been solved.
5
  
The CoaB domain crystallizes as a homodimer and the residues responsible for dimerization 
are conserved in all domains of life.
6
 Dimerization is largely mediated by a dimerization domain 








 in E. coli).
7
 The latter 
region, which contains the highly conserved Lys
298
-X-Lys-Lys (X = Ile in E. coli) motif, reaches 
out to the other protomer as a partially disordered loop that is situated near the entry of the 
neighbouring active site, with Lys
298
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Figure 1 (a) Conversion of PPan into PPC proceeding through an acyl cytidylate intermediate, 
as catalyzed by PPCS. (b) Structures of CoaB inhibitors previously reported. 
 
Kinetic and structural studies have indicated that the nucleobase binding sites of bacterial 
PPCS enzymes
7
 are substantially different from the corresponding human enzyme,
8
 rendering 
PPCS as a promising antimicrobial target.
1
 The bacterial CoaB enzyme has a strict requirement 
for CTP, in contrast to human CoaB which uses ATP about four times more efficiently than it 
does CTP.
9
 In E. coli CoaB (EcCoaB), the nucleotide binding pocket is quite rigid and shows 
strong shape complementarity to the cytosine moiety.
7
 In contrast, human CoaB has an enlarged 
and also more flexible nucleotide binding pocket that confers a preference for ATP, but that still 
can accommodate the smaller CTP molecule.
8
 Recently, Mizrahi and co-workers have 
established the essentiality of CoaBC in a murine model of Mycobacterium tuberculosis 
infection.
10
 Silencing of coaBC was bactericidal regardless of whether knockdown was initiated 
at the time of infection or during either the acute or chronic stages of infection, demonstrating 
that CoaBC is needed for M. tuberculosis to grow and persist in mice. 
The first CoaB inhibitors were reported by Dotson and co-workers in 2009.
11
 These 
compounds are structural mimics of the acyl cytidylate intermediate that forms during catalysis, 
with the reactive acyl-phosphate moiety of the natural intermediate replaced by either a stable 
phosphodiester or sulfamate isostere (Figure 1b). These compounds are non-competitive, slow-
onset and tight-binding inhibitors that exhibit nanomolar IC50 and Ki values against the CoaB 
enzymes of E. coli, Enterococcus faecalis, and Staphylococcus pneumoniae, as well as up to 
1000-fold selectivity over human CoaB. More recently, Burkart, Strauss and co-workers have 
characterized the natural product CJ-15,801,
12
 an antibiotic effective against drug-resistant 
 4 
strains of Staphylococcus aureus (MRSA), as the precursor to a tight-binding inhibitor of CoaB. 
CJ-15,801 structurally resembles Pan (differing only because it has a trans-substituted double 
bond in the β-alanine moiety), and it can be phosphorylated by the S. aureus Pan kinase (PanK) 
to furnish a PPan-like compound (Figure 1b) that binds to the CoaB domain. Subsequent 
cytidylylation by CoaB generates a tight-binding structural mimic of the native acyl cytidylate 
intermediate with nanomolar potency against the E. coli CoaB domain and S. aureus CoaBC.
12
 
However, despite the CoaB enzyme having been characterized over ten years ago, no non-
mimetic inhibitors of CoaB have been reported in the literature. A better understanding of the 
structure and interactions of CoaB could aid the development of therapeutic compounds against 
this promising antimicrobial target. 
Native electrospray ionization-mass spectroscopy (ESI-MS), and particularly native 
nanoelectrospray ionization-mass spectrometry (nESI-MS), has emerged as a powerful technique 
for the study of biomolecular complexes.
13-15
 Moreover, ESI-MS can be interfaced with ion 
mobility (IM) spectrometry, which can provide an orthogonal mode of separation of gaseous 
ions. In ion mobility-mass spectrometry (IM-MS), ions traverse a chamber of neutral gas 
particles under the influence of an electric field, and become separated on the basis of differences 
in their rotationally-averaged collision cross-section (CCS).
16-18
 In this work, native nESI-IM-
MS experiments were conducted to provide structural insights into the EcCoaB domain. Our 
results indicate that CoaB exists in an equilibrium of monomers and dimers in solution, with 
dimer formation being favoured in the presence of CTP. Equilibrium titration experiments 
suggest that the binding of CTP to CoaB is cooperative, and also confirm the preference of 
EcCoaB for CTP over ATP. IM-MS analysis was applied to characterize the size and unfolding 
profiles of the EcCoaB monomer and dimer in the gas phase. Finally, native MS was used to 
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screen a small library of sulfonamide compounds against EcCoaB, revealing a new class of 
small-molecule, non-mimetic inhibitors of CoaBC. 
 
Materials and Methods  
Mass spectrometry  
nESI-IM-MS spectra were recorded on a Synapt HDMS mass spectrometer (Waters, Manchester, 
UK) modified for studying high masses and equipped with a traveling wave (TW) IM cell. 
EcCoaB was exchanged into 200 mM ammonium acetate (pH 7.0, unless otherwise stated) using 
Micro Bio-Spin 6 chromatography columns (Bio-Rad, UK). Protein samples were equilibrated at 
room temperature in the absence or presence of the indicated concentrations of ligands for at 
least 15 min before analysis. An aliquot of protein (2.5 μL) was then injected into a gold-coated 
borosilicate emitter (Thermo Scientific, UK) for sampling. Typical conditions were capillary 
voltage 1.5 kV, cone voltage 50 V, trap collision voltage 20 V, transfer collision voltage 20 V, 
source temperature 20 °C, backing pressure 3–4 mbar, trap pressure 3–4 × 10
–2
 mbar, IM (N2) 
pressure 5–6 × 10
–1
 mbar and time-of-flight (TOF) pressure  
7–8 × 10
–7
 mbar. For IM experiments, the mass spectrometer was operated in mobility TOF 
mode using a wave velocity of 250 ms
–1
 and a wave height of 10 V. To effect collision-induced 
unfolding (CIU), the trap collision voltage was raised in 2 V increments from 10 to 80 V. Avidin, 
concanavalin A, alcohol dehydrogenase and pyruvate kinase were used as calibrants for CCS 
determination. All mass spectra were calibrated externally with cesium iodide (10 mg/mL). Data 




The dissociation constant (Kd) for the EcCoaB monomer-dimer equilibrium was determined 
using the procedure of Zenobi and co-workers,
19
 which was based on earlier work by the group 
of Gabelica.
20
 Briefly, the equilibrium association constant (Ka) relating the EcCoaB monomer 
(M) and dimer (D) concentration is described using equation 1, 






         (1) 
The response factors (RM and RD) governing the relationship between the concentrations of M 
and D and their ion intensities (IM and ID respectively) are described using equations 2 and 3, 
𝐼𝑀 = 𝑅𝑀 × [𝑀]       (2) 
𝐼𝐷 = 𝑅𝐷 × [𝐷]      (3) 
 
Given a total EcCoaB monomer concentration of [M0] (where [M0] = [M] + 2[D]), and setting 












       (5) 
 
After determination of IM and ID from the mass spectra, equation 5 can be solved for R and Ka 
by double-parametric non-linear curve fitting. Non-linear parameter uncertainties were estimated 




Ion mobility calibration 
 7 
Calibration with ions of known CCS is required on a TW-IM instrument because the analytical 
equations governing ion mobility are complex owing to the non-linear time- and space-varying 
dependence of the electric field.
22, 23
 Briefly, the drift times (tD) (in ms) are corrected for mass-
dependent flight time using equation 6, 
 
𝑡′𝐷 = 𝑡𝐷 −
𝐶√(𝑚/𝑧)
1000
        (6) 
 
where t′D is the corrected drift time of the calibrant ions, C is the "EDC (Enhanced Duty Cycle) 
delay coefficient” and is equal to 1.57, and m/z is the mass-to-charge ratio of the observed ion. 
The calibrant CCS (Ω) values are then corrected for both ion charge state (z) and reduced mass 
(μ) according to equation 7, 
 
Ω′ =  
Ω
(𝑧 × √(1/μ))
        (7) 
 
where Ω′ is the corrected CCS value and μ is the reduced mass of the ion-N2 collision complex. 
Next, ln(tD′) is plotted against ln(Ω′) and the slope (X) of the graph is determined. A new 
corrected drift time (t′′D) is then calculated using equation 8, 
 
𝑡′′𝐷 = 𝑡′𝐷 𝑥
𝑋 × 𝑧 × √(1/μ)      (8) 
 
Finally, Ω is re-plotted against t′′D to generate a linear calibration plot that can then be used to 
determine CCS values for analyte ions. Unless otherwise stated, all CCS values are quoted as N2 
values. PULSAR
24
 was used to perform CCS calibration,
23
 generate CIU plots and calculate 
 8 
CIU50 values. As algorithms for CCS calculation from X-ray crystal structures are parameterized 
for helium collision gas,
22
 theoretical CCS(He) values were first determined using the projection 
approximation (PA) algorithm implemented in DriftScope, and then converted to theoretical 
CCS(N2) values as described by Bush et al.
25
 However, the PA algorithm, which functions by 
finding the average projection (or “shadow”) of an ion onto a defined plane, generally 
underestimates CCS values for biomolecules because it does not take into account the greater gas 
slow-down effect for cavities.
22
 To account for this, an empirically-determined scaling factor of 
1.14 is introduced.
14
 Thus, the “corrected” theoretical CCS value (CCScalc) was calculated using 
equation 9, 
 





3     (9) 
 
where CCSPA is the CCS calculated from the X-ray crystal structure using the PA algorithm, 
Mexp is the experimental mass of the protein and MPDB is the mass calculated from the crystal 
structure. In the case of the EcCoaB dimer, CCSPA was determined to be 3482 Å
2
 from the 
reported X-ray crystal structure (PDB: 1U7U),
7
 and Mexp and MPDB were 27942 and 24834 Da, 




Results and Discussion 
Native MS of the EcCoaB domain 
Although the bifunctional EcCoaBC enzyme has been shown by size exclusion chromatography 
to exist as a dodecamer,
4
 the isolated CoaB domain crystallizes as a homodimer.
6
 Strauss and 
Begley have shown that the product of the PPCS (CoaB) reaction is released from EcCoaBC 
 9 
before it returns to a different active site for transformation by PPCDC (CoaC).
26
 Therefore the 
functional significance of the CoaB-CoaC fusion is not currently apparent. As the isolated CoaB 
domain of E. coli is fully functional,
6
 in this study we have used the isolated CoaB domain as a 
surrogate for CoaBC in binding and mechanistic studies. The dimeric EcCoaB enzyme (56 kDa), 
being far smaller than the dodecameric CoaBC protein (ca. 500 kDa), is much more amenable to 
native MS analysis, and easier to express and purify. Doubly-His6-tagged EcCoaB, containing 
residues 182 to 406 of EcCoaBC, was overexpressed and purified in a high yield from E. coli, 
and protein identity and purity were assessed by denaturing LC-MS (Figure S1) and SDS-PAGE 
analysis. 
Typical buffers used for protein expression and purification are incompatible with ESI-MS 
owing to ion suppression as well as the formation of extensive protein-ion adducts. Therefore, 
EcCoaB was first exchanged into 200 mM ammonium acetate (NH4OAc) before native MS 
analysis. The native mass spectrum of EcCoaB alone showed that EcCoaB exists as an 
equilibrium of monomeric and dimeric species (Figure 2a). The EcCoaB monomer, centered 
around the 10+ charge state, had an observed mass of 28002 ± 24 Da which was close to the 
theoretical mass of the protein (without its N-terminal methionine) and the mass observed by 
denaturing LC-MS (27942 Da; Figure S1). Meanwhile, the EcCoaB dimer, centered around the 
15+ charge state, had an observed mass of 55999 ± 42 Da, which was also close to the theoretical 
mass of 55883 Da for two molecules of EcCoaB. The masses of the EcCoaB monomer and 
dimer observed by native MS are slightly higher than the theoretical masses presumably due to 
the adduction of weakly-bound buffer or water molecules to the protein under the soft ionization 
conditions employed.  
[Insert Figure 2] 
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Figure 2 The dimerization of EcCoaB is concentration-dependent. Native mass spectra of 
EcCoaB in 200 mM NH4OAc at (a) 60 μM, (b) 50 μM, (c) 40 μM, (d) 30 μM and (e) 20 μM, 
with monomer (M) and dimer (D) charge states indicated. 
 
Non-covalent interactions in native MS can be affected by the concentration of NH4OAc buffer 
used.
27
 In this study, the effect of NH4OAc concentration on the appearance of the EcCoaB 
native mass spectrum was investigated. At 50 mM NH4OAc, higher-order species corresponding 
to trimers, tetramers, pentamers and hexamers of EcCoaB were observed (Figure S2a). However, 
the abundance of the higher-order species (trimers and above) was greatly diminished at 200 mM 
NH4OAc (Figure S2b) or 500 mM NH4OAc (Figure S2c), suggesting that the oligomers arise as 
a consequence of non-specific aggregation of EcCoaB. This finding is similar to a recent native 
MS study of CK2 kinase, where the oligomerization state of the protein was also found to be 
dependent on ionic strength.
28
 The proportion of monomer and dimer species was similar at 200 
and 500 mM NH4OAc. However, the electrospray became more difficult to maintain at 500 mM 
NH4OAc, therefore a concentration of 200 mM NH4OAc was chosen for subsequent 
experiments. 
 
Determination of affinity of EcCoaB dimerization 
The peak intensities of the different species in the mass spectrum are often considered to be 
proportional to the concentration of those species in solution. However, this assumes that the 
probability of ions being ionized, transmitted, and detected is the same for all species, which may 
not be true for the monomer and dimer of EcCoaB given their different sizes. A more accurate 
equilibrium dissociation constant can be determined by taking into account the fact that the 
 11 
response factors, which are the products of efficiencies of all the processes affecting the signal 
intensities of the ions, may be different for different species. In this study, the method of Zenobi 
and co-workers
19
 (based on an earlier work by Gabelica et al.
20
) was used to fit the equilibrium 
association constant (Ka) of the EcCoaB monomer-dimer equilibrium (equation 1) as well as the 
ratio (R) between the individual dimer (RD) and monomer (RM) response factors (equation 4) 
from the measured peak ion intensities of the dimer (ID) and monomer (IM) according to equation 
5. 
To derive R and Ka, the native mass spectrum of EcCoaB was recorded at different 
concentrations of the enzyme (Figure 2a-e). The results show that as the concentration of protein 
was lowered, the abundance of the EcCoaB dimer decreased relative to the monomer. Using 





(corresponding to Kd = 29 μM), respectively. Figure S3 shows a graph of experimental IM/ID 
values against total EcCoaB monomer concentration (M0) as well as the fitted curve derived from 
nonlinear regression of equation 5. The value of R (1.8) is within the range of 0.5 to 6.7 for 
biomolecules reported in the literature.
19
  
Gabelica and co-workers emphasized that a very high quality data set from the titration 
experiment is required to obtain precise fitting values.
20
 However, in a similar way to that 
observed by Zenobi and co-workers,
19
 the IM/ID values showed significant scatter around the 
fitted curve. Therefore, the confidence intervals that were obtained by fitting the data using 
unconstrained values of R and Ka were relatively broad (Table 1, Entry 1). More precise Ka 
values may be obtained by first constraining the choice of R. With reference to Zenobi and co-
workers,
19
 the fitted Ka values when R was restricted to 1, 2 or 4, were determined to be 8.6 × 
10
4
, 2.9 × 10
4




 respectively (Table 1, Entries 2–4). The Ka values decrease with 
 12 
R as expected because increasing the value of R (the ratio of response factors between the dimer 
and the monomer) decreases the estimated dimer to monomer concentration ratio. The Kd values 
determined suggest that the interaction between two EcCoaB monomers is of low affinity.  
 
Table 1. R and Ka values obtained by nonlinear regression of equation 5, using data obtained 
from the EcCoaB titration experiment (Figure 2). Corresponding Kd values (where Kd = Ka
–1
) are 
shown to aid interpretation. 95% confidence intervals determined by the Monte Carlo method are 
shown in parentheses.  




 Kd / M 
1
a
 1.8 (0.9-3.0) 3.5 (1.6-5.4) 29 (19-63) 
2 1 8.6 (7.7-9.3) 12 (11-13) 
3 2 2.9 (2.7-3.1) 34 (32-37) 
4 4 1.1 (1.0-1.2) 91 (83-100) 
 
a
R was unconstrained. This gave broader confidence intervals for both R and Ka. In entries 2–4, 
R was constrained to 1, 2 or 4 respectively to generate more precise estimates for Ka. 
 
Influence of solution pH on EcCoaB dimerization:  
Since pH governs the strength of many protein-protein interactions, it is of interest to 
determine the influence of solution pH on the dimerization of the EcCoaB domain. The native 
mass spectra of EcCoaB at pH values of 7.0, 5.0 and 3.0 are shown in Figure 3. The spectra show 
that the native mass spectra of EcCoaB at pH 7 (Figure 3a) and pH 5 (Figure 3b) are broadly 
similar, except for a slight decrease in EcCoaB dimer abundance and the appearance of higher 
 13 
charge states of the monomer (13+ and 14+), suggesting the partial unfolding of the protein. 
However, the appearance of the spectrum was dramatically changed at pH 3 (Figure 3c). The 
dimer completely disappeared, and instead, a series of highly-charged monomeric EcCoaB ions 
were observed and accompanied by the appearance of aggregates in the higher m/z region. All of 
these features are indicative of the chemical denaturation of EcCoaB. As the protein unfolds, its 
surface area increases, which allows for a greater accumulation of positive charge on the 
molecule during the electrospray process. The exposure of interior lipophilic residues could 
allow the protein to interact via hydrophobic interactions to form higher-order aggregates. 
Additionally, the lowering of the pH is likely to disrupt polar interactions that are important for 
dimerization, leading to the disruption of the EcCoaB protein-protein interface even while some 
of the monomer remains natively folded (as indicated by the intact charge envelope 
encompassing the 9+ to 12+ charge states of the monomer in Figure 3c).
7
 This suggests that the 
tertiary structure of the EcCoaB monomer is relatively more resistant to acid-induced 
denaturation than the quaternary interactions between the protomers in the dimer. 
 
[Insert Figure 3] 
 
Figure 3 Lowering of pH disrupts EcCoaB dimerization and partially unfolds the protein. 
Native mass spectra of EcCoaB (30 μM) in 200 mM NH4OAc at (a) pH 7, (b) pH 5, and (c) pH 
3, with monomer (M), dimer (D) and unfolded monomer (U) charge states indicated. For clarity, 
charge states for the unfolded monomer are not assigned in (c). The molecular masses of the 






Ion mobility-mass spectrometry of EcCoaB 
IM-MS is a technique that separates gaseous ions of different size and shape, based on 
differences in their mobility through a drift cell of neutral gas particles in the presence of an 
electric field.
16
 In general, compact ions (low CCS) travel faster through the drift cell than 
extended ions (high CCS), due to fewer collisions with the neutral gas. IM-MS therefore 
provides an orthogonal dimension of resolution compared to MS alone, and can provide 
topological information that is complementary to other structural biological techniques.
18
 In this 
study, IM-MS experiments were performed to investigate the structural characteristics of 
EcCoaB in the gas phase. 
Table 2 presents CCS values for individual charge states of the EcCoaB monomer and dimer at 
either 0 or 5% (v/v) DMSO. CCS values generally increase with charge state, which could be due 
to the increased internal electrostatic repulsion of protein ions at higher charge. At 0% DMSO, 
the population-weighted average CCS of the EcCoaB monomer and dimer ions are 2556 ± 77 
and 4147 ± 124 Å
2
, respectively. For comparison, the theoretical CCScalc of the EcCoaB dimer 
calculated from the X-ray crystal structure (PDB: 1U7U)
7
 was 4258 Å
2
. As the experimental and 
theoretical CCS values are in agreement within the limits of experimental error, this suggests that 
the EcCoaB dimer remains natively folded in the gas-phase. In contrast, the experimental CCS of 
the EcCoaB monomer (2576 ± 79 Å
2
) was 5% higher than the theoretical CCS (2460 Å
2
) of a 
model of the monomer generated by artificial truncation of the dimer structure. This may be 
because the EcCoaB monomer adopts a slightly more extended conformation when it is not 





Table 2. CCS values of EcCoaB monomer and dimer ions as determined by IM-MS at 0 and 
5% (v/v) DMSO. The population-weighted average CCS values of the monomer and dimer 





CCS / Å2 
(0% DMSO) 
CCS / Å2 
(5% DMSO) 
Charge state 
CCS / Å2 
(0% DMSO) 
CCS / Å2 
(5% DMSO) 
8+ - 2307 11+ - 3674 
9+ 2358 2407 12+ - 3747 
10+ 2502 2542 13+ - 3841 
11+ 2755 - 14+ 3938 3945 
12+ 3028 - 15+ 4031 - 
   16+ 4199 - 
   17+ 4442 - 
Average 2556 2382 Average 4147 3803 
 
In the presence of 5% (v/v) DMSO, the charge state distributions of both the EcCoaB monomer 
and dimer shifted to lower charge states (Figure S4). This is accompanied with a compaction of 
the protein structure (average CCS values are lowered by 7–8%, Table 2), and is consistent with 
previous studies on the effects of DMSO on protein size both in solution and in the gas phase.
29-
31
 However, the relative abundance of monomers and dimers was not substantially changed by 
the presence of DMSO. 
 
Collision-induced unfolding of EcCoaB 
The use of collisional activation to generate unfolding plots (or “fingerprints”) is a recently 




Collision-induced unfolding (CIU) fingerprints are obtained by recording the native mass spectra 
of a protein at incrementally higher acceleration voltages within the collision cell of a mass 
spectrometer. As protein ions unfold through collisions with neutral gas molecules, changes in 
their CCS can be tracked as a function of collision voltage, allowing the quantitation of a 
protein’s resistance to unfolding in the gas phase. CIU IM-MS experiments have been used, for 
example, to evaluate the effects of ligands on protein stability,
24
 or to differentiate between Type 




[Insert Figure 4] 
Figure 4. CIU IM-MS reveals gas-phase unfolding transitions of EcCoaB. CIU fingerprints of 
indicated charge states of the EcCoaB (a) monomer (M) and (b) dimer (D). For the 9+ state of 
the monomer, native-like (N), intermediate (I) and extended (E) forms of the protein are labeled. 
 
The CIU fingerprints for EcCoaB monomeric (Figure 4a) and dimeric (Figure 4b) ions are 
complex and reveal multiple unfolding transitions over the range of collision voltages tested. For 
instance, for the 9+ state of the monomer, the native-like protein (N, CCS ≈ 2400 Å
2
) initially 
transitions into a partially unfolded intermediate form (I, CCS ≈ 2800 Å
2+
) at moderate collision 
voltages, then shifts into a more extended form (E, CCS ≈ 3100 Å
2+
) as the collision energy is 
increased further. It is assumed that E represents the most unfolded form of the monomeric 9+ 
ion as populations with larger CCS values were not observed even as the collision voltage was 
increased to 150 V, at which point protein degradation also began to occur (data not shown). The 
CIU50 values of the native-like (N) and intermediate (I) forms of the monomeric 9+ ion (i.e. the 
collision voltage needed to deplete 50% of the population of the conformation) were determined 
 18 
to be 34 and 62 V, respectively. For the other monomeric and dimeric EcCoaB charge states, 
multiple intermediate species were observed in the CIU plots, indicative of complicated 
unfolding pathways for those ions.  
CIU plots for EcCoaB monomeric 9+ and 10+ states are broadly similar in the presence of 5% 
(v/v) DMSO (Figure S5a) compared to the respective plots in the absence of DMSO. The 8+ 
state of the monomer, accessible only via charge reduction conditions with DMSO, did not 
unfold even at the highest collision voltages tested. The greater CIU stability of lower charge 
states is known 
31, 34
 and can be attributed to the lesser internal electrostatic repulsion 
experienced by proteins of lower charge. For the EcCoaB dimer in the presence of DMSO, the 
11+ state did not unfold, while the 12+ and 13+ states underwent one and three unfolding 
transitions respectively over the collision voltage range tested (Fig. S5b). 
 
 
Interaction of EcCoaB with CTP 
Since EcCoaB utilizes CTP to activate the carboxylate group of PPan, the interaction between 
CTP and EcCoaB was studied by native MS. Interestingly, the addition of 50 μM CTP to 
EcCoaB (25 μM) (Figure 5b) increased the proportion of dimeric EcCoaB relative to the 
proportion present in the absence of CTP (Figure 5a). With CTP present, the Kd value for the 
monomer-dimer equilibrium was estimated to be 4 μM, which is substantially lower than the 
corresponding Kd value of 29 μM determined in the absence of CTP (Table 1). This result 
indicates that CTP stabilizes the dimeric form of EcCoaB, and is consistent with the observation 




 The proportion of dimer was further increased at higher concentrations of CTP (Figure 
S6a-e), and at 200 μM CTP, only a small amount of the monomer could be detected.  
At 50 μM CTP, 66% of the EcCoaB monomer was unbound while 34% was singly-bound by 
CTP (Figure 5b). In contrast, the majority of the dimer was observed in singly-bound (32%) or 
doubly-bound (38%) states. This can also be rationalized on the basis that the CTP-binding site 
of EcCoaB is formed of residues from both subunits of the dimer.
7
 Therefore, the binding 
affinity of CTP for the monomer would be expected to be weaker than for the dimer.  
 
 
[Insert Figure 5] 
 
 
Figure 5 EcCoaB selectively binds CTP over ATP, and CTP stabilizes the dimer. Native MS 
of EcCoaB (25 μM) in the (a) absence, or presence of (b) CTP (50 μM) or (c) ATP (50 μM). In 
(a), the monomer (M) and dimer (D) charge states are indicated. In (b) and (c), the number of 
ligands bound to each monomer or dimer species is indicated. 
 
A small amount (17%) of the EcCoaB dimer was bound to three molecules of CTP (Figure 
5b). As each dimer only has two CTP-binding sites, this suggests that the third molecule of CTP 
is bound non-specifically to the protein. The observation that non-specific binding is observed at 
only a mild excess of CTP over protein (50 μM of CTP vs 25 μM of EcCoaB) could possibly be 
accounted for by the fact that electrostatic interactions, which are presumably significant 
between the doubly-anionic CTP molecule and the positively-charged EcCoaB protein, are 
 20 
generally thought to be strengthened in the gas phase. In previous native MS studies, a high 
degree of non-specific binding was also observed between creatine kinase and ATP,
35
 and 
between GroEL and ATP.
36
 With EcCoaB, non-specific binding was even more pronounced at 
higher CTP concentrations, with up to four CTP molecules bound per dimer at 200 μM of CTP, 
and two molecules of CTP bound per monomer (Figure S6e).  
Several methods have been developed to tackle the issue of non-specific binding in native ESI-
MS experiments. van der Rest and co-workers
35
 developed a deconvolution method that modeled 
the specific binding as a binomial distribution and the non-specific binding as a Poisson 
distribution (which was originally proposed by Klassen and co-workers).
37
 Alternatively, Guan 
and co-workers have modeled the non-specific component as a power-law distribution,
38
 while in 
yet another approach, the group of Sharon and Horovitz have modeled all non-specific sites with 
a single binding constant.
39
 
In this study, to isolate the effect of non-specific binding in this system, the interaction 
between EcCoaB and ATP was monitored using native MS. The native mass spectrum of 
EcCoaB in the presence of ATP (50 μM) is shown in Figure 5c. As expected, the proportion of 
EcCoaB dimer was not increased by the addition of ATP, unlike with CTP. This indicates that 
ATP does not stabilize the EcCoaB dimer, presumably because it is too large to enter into the 
nucleobase binding pocket of the enzyme. Moreover, ATP showed weaker binding to the dimer 
compared to CTP, as reflected by the lower proportion of ligand-bound protein for ATP 
compared to CTP at the same concentration. Based on the findings of Strauss et al.,
3
 which 
showed that EcCoaB enzyme activity was not promoted even at up to 10 mM of ATP, we 
assumed that EcCoaB-ATP complexes observed by native MS were non-specific. With this 
assumption, the specific binding component of CTP can be estimated by subtracting the 
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occupancy of ATP from the occupancy of CTP at each site of the protein. Applying this method 
to the data shown in Fig. 5 revealed that the specific binding constant of CTP to the monomer is 
380 μM, while the average specific binding constant of CTP to the two sites of the dimer is 70 
μM. The latter affinity is composed of a specific binding constant of 580 μM for the first CTP 
molecule binding to the dimer, and a specific binding constant of 9 μM for the second CTP 
molecule binding to the dimer, which indicates some degree of positive cooperativity in the 
binding. The average specific binding constant (70 μM) is also consistent with the KM value of 




Screening for EcCoaB inhibitors by native MS 
Due to its ability to detect protein-ligand interactions, native MS is finding increasing use as a 
compound screening technique, including in fragment-based drug discovery (FBDD).
40-42
 In line 
with our continuing interest in the application of FBDD methods to develop new antimicrobial 
compounds, native MS was applied to screen a small library of fragment-sized sulfonamides 
against EcCoaB. These analogues were designed and synthesized based on the structure of 
sulfonamide fragment hit 1 that was identified in a fragment screen using a combination of 
differential scanning fluorimetry and ligand-based NMR studies (data not reported). The library 
of analogues 2-11 retain the sulfonamide core of fragment 1, but have simpler aromatic motifs in 
place of the synthetically challenging aniline and pyrimidine moieties of 1 (Figure 6).  
 
[Insert Figure 6] 
Figure 6 Structures of sulfonamide compounds 1-11 examined in this work. 
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Additionally, the structure-activity relationships (SAR) around the phenyl substituent attached 
to the sulfonamide nitrogen atom were investigated by the installation of a carboxyl group and/or 
a bromine atom at various positions of the ring (except for compound 9, which carries a 2-
methoxypyridin-3-yl substituent in place of the phenyl ring). All of the library compounds (with 
the exception of naphthalene compound 11) have either 19 or 20 heavy atoms, putting them close 
to the upper limit in size of typical fragments. The synthesis and characterization of compounds 
2–11 are described in the Electronic Supplementary Information. 
 To minimize non-specific binding, the compounds were tested at a concentration of 30 
μM with EcCoaB at 15 μM, giving only a 2:1 excess of ligand to protein. The native mass 
spectra of EcCoaB incubated with compounds 1-11 are shown in  
Figure 7. The DMSO concentration was 1% (v/v). In general, the compounds did not increase the 
ratio of the dimer to the monomer, indicating that unlike CTP they do not stabilize the EcCoaB 
dimer. This result is not surprising as the compounds are significantly smaller than CTP and thus 
less likely to be able to simultaneously contact both subunits of the dimer, even if they were 
binding to the CTP-binding site.  
 The native MS screen revealed five hits (compounds 4, 5, 6, 9 and 11) that bound to 
EcCoaB, as indicated by the appearance of additional peaks corresponding to the mass of the 
protein-ligand complex in the spectra. Due to the relatively small size of the ligands, only ligands 
bound to the monomer could be discretely resolved. For compounds 6 and 11, a small proportion 
of doubly-bound EcCoaB monomer species was observed, which could either represent non-
specific binding, or possibly two fragments binding at the same time to the active site.  
 To validate the screening hits, they were tested for EcCoaB inhibitory activity using an 
enzymatic assay. In this assay, the production of pyrophosphate that occurs concomitantly with 
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the first half-reaction catalyzed by EcCoaB (the formation of 4’-phosphopantothenoyl-CMP) was 
monitored. As EcCoaB was used as a surrogate for the bifunctional EcCoaBC in the MS studies, 
EcCoaBC (16 nM) was used in the enzymatic assay to ensure that inhibitors identified were 
biologically relevant. At a concentration of 1 mM (and CTP, phosphopantothenate and L-cysteine 
at concentrations of 125, 125 and 500 µM, respectively (see Supporting Information)), the initial 
sulfonamide fragment 1 showed the weakest EcCoaBC inhibitory activity of 6 ± 3%, while the 
most potent compound was the naphthalene analogue 11, which inhibited EcCoaBC activity by 
92 ± 5% (Table S1). Pleasingly, there was good agreement between the results of the native MS 
assay and the biochemical assay. The five native MS hits (compounds 4, 5, 6, 9 and 11) were 
also the five most active compounds in the biochemical assay, with an average EcCoaBC 
inhibition of 57% at 1 mM (range of 29 to 92%) (Figure S7). Conversely, the compounds that 
were not detected to bind by native MS (compounds 1, 2, 3, 7, 8 and 10) showed the lowest 
activity in the biochemical assay, with an average inhibitory value of 18% (range of 6 to 25%). 
Taken together, these results validate the use of native MS with monofunctional EcCoaB as a 
simple and rapid screening technique for identifying inhibitors of EcCoaBC. In future work, 
native MS could be used to derive binding affinities for the inhibitors identified here (as was 
done for CTP) and the correlation between MS-determined binding affinities for EcCoaB and 
inhibitory activity against EcCoaBC explored.  Moreover, CIU IM-MS could be used to 
investigate the effect of the inhibitors and other known ligands on EcCoaB stability.  
[Insert Figure 6] 
Figure 7 Screening of sulfonamide compounds 1-11 against EcCoaB by native MS. In each 
experiment, the protein concentration was 15 μM and the ligand concentration was 30 μM. For 
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the screening hits (compounds 4, 5, 6, 9 and 11), the number of ligands bound to each monomer 
species is indicated. 
 
Conclusions 
In this work, native nESI-IM-MS has been conducted to provide structural insights into the 
EcCoaB domain of EcCoaBC. While EcCoaB crystallizes as a dimer, our experiments 
demonstrate that in solution an equilibrium exists between the monomer and dimer. Dimer 
formation can be promoted by CTP, but not ATP, which is consistent with previous structural 
and biochemical data. The gas-phase unfolding behavior of monomeric and dimeric EcCoaB 
ions was studied by IM-MS, revealing complex CIU fingerprints for most charge states. Finally, 
native MS was applied to screening of a small library of fragment-sized sulfonamide compounds 
against EcCoaB, and the hit compounds were validated using a biochemical assay. Good 
agreement was observed between the native MS binding studies with EcCoaB and the enzyme 
inhibition assays performed with EcCoaBC. The active sulfonamide compounds represent a new 
class of small-molecule, non-mimetic inhibitors of CoaBC, a recently validated antimicrobial 
target. This study thus highlights the utility and versatility of native MS both for structural 
biology and for drug discovery.  
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Synthetic chemistry methods: All chemicals were of reagent grade quality or better, 
obtained from commercial suppliers and used without further purification. 4’-
Phosphopantothenate was synthesised following a literature procedure (Eur. J. Org. Chem., 
2010, 1728). Unless otherwise stated, reactions were conducted under positive pressure of a 
nitrogen atmosphere. Anhydrous solvents were purchased directly from commercial sources 
and used without further purification. Analytical thin layer chromatography (TLC) was 
performed using Merck glass-backed silica (Kieselgel 60 F254 0.25 mm) plates. Compounds 
were visualized using shortwave (254 nm) ultraviolet light. Flash column chromatography 
was performed using an Isolera Spektra One/Four purification system and the appropriately 
sized Biotage SNAP column containing KP-silica gel (50 μm). Solvents are reported as 
volume/volume eluent mixtures. Reactions were monitored by TLC and liquid 
chromatography-mass spectrometry (LC-MS) to determine consumption of starting materials. 
Nuclear magnetic resonance (NMR) spectra were recorded at 298 K unless otherwise stated, 
using either a Bruker 400 MHz AVANCE III HD Smart Probe, 400 MHz QNP cryoprobe, or 
500 MHz DCH cryoprobe spectrometer. All spectra were recorded in the deuterated solvent 
indicated. Data are reported as chemical shift in parts per million (δ ppm) relative to the 
residual protonated solvent resonance peak. The relative integral, multiplicity and coupling 
constants (J Hz) of peaks has been provided where possible. LC-MS was carried out using an 
AQUITY UPLC H-class system (Waters, Manchester UK). Samples were run using a 
gradient of water (1−5%) (+0.1% formic acid) in acetonitrile over a period of 4 min. High 
resolution mass spectra (HRMS) were recorded using a Micromass Quadrapole-Time-of-
Flight (Q-Tof) spectrophotometer or an Orbitrap LC-MS spectrometer attached to a Dionex 
Ultimate 3000 HPLC. The mass to charge ratio (m/z) of the molecular ion and difference 
from calculated mass (δ ppm) are quoted. 
Overexpression and purification of E. coli CoaB (EcCoaB). A pET-28b plasmid carrying 
the coding sequence for the CoaB domain of E. coli CoaBC (EcCoaBC) was used. The 





-LEHHHHHH, CoaBC residues 
indicated).  E. coli BL21(DE3) cells transformed with the construct were grown in LB 
supplemented with 30 µg/mL kanamycin until an OD600 of approximately 0.6 was reached. 
Immediately thereafter overexpression was induced by the addition of 1 mM isopropyl--D-
 4 
1-thiogalactopyranoside (IPTG). After overnight incubation at 37 °C, the bacteria were 
harvested by centrifugation (4000  g, 15 min) and the cell pellet was stored at –20 °C.  The 
harvested cells were lyzed in 20 mM Tris, 500 mM NaCl, pH 8.0 containing one EDTA-free 
cOmplete protease inhibitor cocktail tablet (Roche) per 50 mL lysate, using an EmulsiFlex-
C5 High Pressure Homogenizer (Avestin). The cells were passed through the pressure cell 
three times at a pressure of 40 000 psi, after which the lysate was centrifuged at 35 000  g 
for 30 min. For nickel-affinity chromatography, the clarified lysate was applied to a 5 mL 
HisTrap FF column (GE Healthcare) and, following washing with lysis buffer, the His-tagged 
protein was eluted using a linear gradient of imidazole (0–0.5 M). Elution was monitored at 
A280 and by SDS-PAGE analysis. Fractions containing EcCoaB were pooled and 
concentrated using a Vivaspin 20 centrifugal concentrator with a 10 kDa molecular weight 
cut-off before being subjected to gel filtration using a Superdex75 26/60 column (GE 
Healthcare) previously equilibrated with 20 mM Tris, 150 mM NaCl, pH 8.0. Gel filtration 
was performed at a flow rate of 2.5 mL/min and elution was again monitored at A280 and by 
SDS-PAGE analysis. Fractions containing purified His-tagged EcCoaB were pooled and 
concentrated as before, and aliquots of the concentrated protein were flash-frozen in liquid N2 
and stored at –80 °C. The identify and purity of EcCoaB was assessed by denaturing LC-MS 
(Figure S1), which showed a mass for the protein that was identical to the theoretical mass of 
the protein without the N-terminal methionine (27942 Da). 
Overexpression and purification of EcCoaBC. EcCoaBC was overexpressed in E. coli 
BL21(DE3) cells from a codon-optimized pET-28a construct. Transformed cells were grown 
at 37 °C in LB culture medium containing 50 μg/mL kanamycin to an OD600 of 
approximately 0.5, then expression was induced with 500 M IPTG. The culture was 
incubated for a further 20 h at 20 °C, and the cells were pelleted by centrifugation (4000  g, 
20 min). Cell pellets are frozen and stored at -80 °C. Cells were resuspended in lysis buffer 
(50 mM Hepes, pH 7.4, 1 M NaCl, 25 mM imidazole, 1 Pierce Protease Inhibitor tablet), and 
lyzed by sonication for 3.5 min (10 s on/20 s off, amplitude 50%). Insoluble material was 
removed from the lysate by centrifugation at 30 000  g for 30 min at 4 °C. The supernatant 
was then loaded onto a 5 mL HisTrap FF column (GE Healthcare), which had been pre-
equilibrated with lysis buffer. The column was further washed with lysis buffer, and then 
EcCoaBC was eluted from the column by increasing the imidazole concentration to 500 mM. 
The eluate was concentrated to ≤10 mL and injected onto a Superdex-200 Hiload 16/60 
FPLC column (GE Healthcare) previously equilibrated with 50 mM Tris (pH 8.0), 250 mM 
 5 
NaCl, and 5 mM 2-mercaptoethanol. The purified protein was concentrated and aliquots were 
flash-frozen in liquid N2 and stored at −80 °C. 
Phosphopantothenoylcysteine synthetase assay. Phosphopantothenoylcysteine synthetase 
activity was monitored by the method of Webb (Proc. Natl. Acad. Sci. USA, 1992, 89, 4884-
4887) using the commercially available EnzChek pyrophosphate assay kit (E-6645) (Life 
Technologies).  The assay couples production of pyrophosphate to the phosphorolysis of 2-
amino-6-mercapto-7-methylpurine ribonucleoside (MESG), which can be monitored by 
measuring absorbance at 360 nm. Reactions were performed at 25 ˚C in the wells of a 96-
well plate (Greiner), in a final volume of 150 µL. The final composition of reactions was 16 
nM EcCoaBC, 125 µM CTP, 125 µM 4’-phosphopantothenate, 500 µM L-cysteine, 0.03 
U/mL inorganic pyrophosphatase, 1 U/mL purine nucleoside phosphorylase, 200 µM MESG, 
100 mM Tris, pH 7.6, 1 mM MgCl2, 1 mM TCEP, and 1 mM of test compound (initially 
dissolved to 50 mM in DMSO) or an equivalent concentration of DMSO (2%, v/v). Initially, 
100 mM Tris, pH 7.6, 1 mM MgCl2, 1 mM TCEP with CTP, 4’-phosphopantothenate, L-
cysteine, MESG and the test compound/DMSO, each at twice the final concentration, in a 
final volume of 75 µL, was added in triplicate to the wells of a 96-well plate, and the plate 
was pre-incubated at 25 ˚C for 10 min.  A 100 mM Tris, pH 7.6, 1 mM MgCl2, 1 mM TCEP 
solution containing EcCoaBC, inorganic pyrophosphatase and purine nucleoside 
phosphorylase, each at twice the final concentration, was also prepared and similarly pre-
incubated at 25 ˚C for 10 min.  Reactions were subsequently initiated by the addition of 75 
µL of the enzyme solution to each well, and enzyme activity was immediately monitored by 
measuring absorbance at 360 nm at 20 s intervals over 30 min in a ClarioStar microplate 
reader (BMG Labtech). Assays were performed in triplicate, and included wells without 4’-
phosphopantothenate, which served as “no reaction” controls, as well as wells containing 2% 
(v/v) DMSO instead of test compound, which served as “uninhibited” controls. Initial 
reaction rates were determined from the linear portion of the time courses. To convert the 
reaction rates measured in the presence of each test compound to a percentage inhibition, the 
average rate determined for the “no reaction” wells was first subtracted from all initial rates. 
Thereafter the background-corrected rates obtained for the wells containing test compound 
were subtracted from the average of the background-corrected uninhibited controls, and then 















Figure S2. The oligomerization of EcCoaB is NH4OAc concentration dependent. Native 
mass spectra of EcCoaB in (a) 50 mM, (b) 200 mM and (c) 500 mM NH4OAc buffer, with 





Figure S3. Plot of the ratio (IM/ID) of the monomer (IM) and dimer (ID) peak intensities (filled 
circles) against the total concentration of EcCoaB monomer (M0) (see Fig. 2 for titration 
experiment). The solid line represents the fitted curve obtained by non-linear regression of 
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Figure S4. DMSO shifts charge state distributions of EcCoaB to lower charge states. Native 


















Figure S5. Collision-induced unfolding (CIU) ion mobility-mass spectrometry (IM-MS) of 
EcCoaB in the presence of DMSO. CIU plots of indicated charge states of the EcCoaB (a) 
















Figure S6. Titration of CTP into EcCoaB reveals non-specific binding at higher CTP 
concentrations. Native mass spectra of EcCoaB (30 μM) in the presence of (a) 0 μM, (b) 30 
μM, (c) 50 μM, (d) 100 μM and (e) 200 μM of CTP. In (a), the monomer (M) and dimer (D) 
charge states are indicated. In (b)–(e), the number of CTP molecules bound to each monomer 










Figure S7. Inhibition of the phosphopantothenoylcysteine synthetase activity of EcCoaBC by 
compounds 1–11 at 1 mM as measured by an enzymatic assay. EcCoaBC, CTP, 
phosphopantothenate and L-cysteine concentrations of 16 nM, 125 µM, 125 µM and 500 µM, 
respectively. Native MS hits (4, 5, 6, 9 and 11) were observed to inhibit enzymatic activity by 
an average of 57%. Native MS misses (1, 2, 3, 7, 8 and 10) inhibited enzymatic activity by an 
average of 18%. The errors bars represent the standard deviation of three experiments.  
 
Table S1. EcCoaBC inhibition activity of compounds (1-11) at 1 mM as measured by 
an enzymatic assay. 
Compound  Structure % inhibition of 
EcCoaBC at 1 mM 
Native MS hit 
1 
 
6 ± 3 - 
2 
 
15 ± 4 - 
3 
 























34 ± 4 Yes 
5 
 
83 ± 5 Yes 
6 
 
46 ± 4 Yes 
7 
 
28 ± 8 - 
8 
 
13 ± 2 - 
9 
 
29 ± 5 Yes 
10 
 
25 ± 5 - 
11 
 







































































Synthesis of compounds 
3-(Phenylsulfonamido)benzoic acid (2)  
 
3-Aminobenzoic acid (0.10 g, 0.73 mmol) was suspended in H2O (7.5 mL) and 
benzenesulfonyl chloride (0.15 g, 0.87 mmol) was added to the suspension with vigorous 
stirring. 1,4-Dioxane (2 mL) was added and the reaction mixture was heated a 37 °C for 2 h, 
and then allowed to cool to room temperature. The aqueous layer was extracted with EtOAc 
and the combined organic layers were dried with MgSO4, filtered, and the solvent was 
evaporated to afford the crude product, which was purified on a flash silica column using an 
Isolera (Biotage) (SNAP KP-Sil 12 g column, 15 mL/min, A = CH2Cl2; B = MeOH, 0%B 
5CV, 0%B-3%B 4CV, 3%-8%B 7.5CV, 8%B 4.5CV) to give the desired product 3-
(phenylsulfonamido)benzoic acid as a colorless powder. Yield: 53% (0.11 g, 0.39 mmol). 
1
H NMR (d6-acetone, 400 MHz) δ 9.22 (s, 1H), 7.91 (t, J = 3.6 Hz, 1H), 7.83-7.81 (m, 2H), 
7.73 (dt, J = 7.6 Hz, J = 2.6 Hz, 1H), 7.63-7.59 (m, 1H), 7.55-7.51 (m, 2H), 7.50-7.47 (m, 
1H), 7.42-7.38 (m, 1H). 
13
C NMR (d6-acetone, 100 MHz) δ 167.0, 140.6, 139.1, 133.8, 132.5, 
130.3, 130.0, 127.9, 126.4, 125.7, 122.4. LC-MS (ESI
-
) m/z 276.1 [M-H]
-
, retention time 1.61 
min (100%). HRMS (ESI
-
) m/z (calcd C13H10NO4S [M-H]
-
 = 276.0336), obsd. 276.0335. IR 
(neat, cm
-1
): 3254, 1682, 1588, 1301, 1267, 1158. 
 
2-(Phenylsulfonamido)benzoic acid (3) 
 
2-Aminobenzoic acid (0.10 g, 0.73 mmol) was suspended in H2O (7.5 mL) and 
benzenesulfonyl chloride (0.15 g, 0.87 mmol) was added to the suspension with vigorous 
stirring. 1,4-Dioxane (2 mL) was added and the reaction mixture was heated at 37 °C for 2 h, 
and then allowed to cool to room temperature. The aqueous layer was extracted with EtOAc 
and the combined organic layers were dried with MgSO4, filtered, and the solvent was 

















column using an Isolera (Biotage) (SNAP C18 12 g column, 15 mL/min, A = H2O with 0.1% 
formic acid; B = CH3CN, 5%B 1CV, 5%B-95%B 10CV, 95%B 4CV) to give the desired 
product 2-(phenylsulfonamido)benzoic acid as a colorless powder. Yield: 34% (0.07 g, 0.25 
mmol).  
1
H NMR (d6-acetone, 400 MHz) δ 8.01 (dd, J = 8.1 Hz, J = 1.6 Hz, 1H), 7.90-7.87 (m, 2H), 
7.72-7.70 (m, 1H), 7.64-7.52 (m, 4H), 7.12 (td, J = 8.1 Hz, J = 1.1 Hz, 1H). 
13
C NMR (d6-
acetone, 100 MHz) δ 170.6, 141.7, 140., 135.4, 134.1, 132.6, 130.1, 128.0, 123.9, 119.4, 
117.1. LC-MS (ESI
-
) m/z 276.1 [M-H]
-





 = 276.0336), obsd. 276.0329. IR (neat, cm
-1
): 3120 (br), 1679, 
1580, 1493, 1390, 1257, 1158. 
 
Ethyl 5-bromo-2-(phenylsulfonamido)benzoate (4a)  
 
Ethyl 2-amino-5-bromobenzoate (0.202 g, 0.829 mmol) was dissolved in pyridine (2 mL) and 
cooled to 0 °C using an ice bath. Benzenesulfonyl chloride (0.12 mL, 0.940 mmol) was added 
dropwise to the reaction and the mixture was stirred at 0 °C for 1.5 h. Ice was added. The 
pink precipitate that formed was then isolated by vacuum filtration. The crude product was 
purified on a flash silica column using an Isolera (Biotage) (SNAP KP-Sil 24 g column, 12 
mL/min, A = petroleum ether; B = EtOAc, 20%B 1CV, 20%B-58%B 6.2CV) to give the 
product ethyl 5-bromo-2-(phenylsulfonamido)benzoate as a colorless solid. Yield: 75% 
(0.239 g, 0.62 mmol). 
1
H NMR (d6-DMSO, 400 MHz) δ 10.35 (s, 1H), 7.92 (d, J = 2.6 Hz, 1H), 7.79-7.75 (m, 3H), 
7.68 (m, 1H), 7.59-7.55 (m, 2H), 7.39 (d, J = 8.9 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 1.28 (t, 
3H). 
13
C NMR (d6-DMSO, 100 MHz) δ 165.7, 138.5, 137.5, 136.81, 133.7, 133.1, 129.5, 
126.9, 122.7, 121.0, 116.0, 62.0, 13.8. LC-MS (ESI
-
) m/z 384.0 [M-H]
-
, retention time 2.48 
min (100%). HRMS (ESI
+
) m/z (calcd C15H15BrNO4S [M+H]
+
 = 383.9905), obsd. 383.9892. 
IR (neat, cm
-1












5-Bromo-2-(phenylsulfonamido)benzoic acid (4)  
 
Ethyl 5-bromo-2-(phenylsulfonamido)benzoate (0.100 g, 0.259 mmol) was dissolved in 
ethanol (2 mL) and sodium hydroxide solution (2 M in H2O, 2 mL, 4 mmol) was added. The 
mixture was heated at 50 °C for 1 h. The solvent was removed in vacuo and H2O (10 mL) 
and DCM (10 mL) were added. The layers were separated and then the aqueous layer was 
acidified with hydrochloric acid solution (3 M) and a white precipitate formed. The product 
5-bromo-2-(phenylsulfonamido)benzoic acid was collected by vacuum filtration as a 
colorless powder. Yield: 53% (0.049 g, 0.14 mmol). 
1
H NMR (d6-DMSO, 400 MHz) δ 11.11 (s, 1H), 7.95 (d, J = 2.5 Hz, 1H), 7.82-7.80 (m, 2H), 
7.75-7.72 (m, 1H), 7.68-7.65 (m, 2H), 7.46 (d, J = 8.8 Hz, 1H). 
13
C NMR (d6-DMSO, 100 
MHz) δ 168.4, 138.9, 138.4, 137.0, 133.8, 133.6, 129.6, 126.9, 120.8, 119.2, 115.1. LC-MS 
(ESI
-
) m/z 356.0 [M-H]
-
, retention time 2.16 min (100%). HRMS (ESI
+
) m/z (calcd 
C13H10BrNO4S [M+Na]
+
 = 377.9406), obsd. 377.9400. IR (neat, cm
-1
): 3216 (br), 1703, 
1667, 1573, 1478, 1448.  
 
4-Bromo-2-(phenylsulfonamido)benzoic acid (5) 
 
2-Amino-4-bromobenzoic acid (0.15 g, 0.69 mmol) was suspended in H2O (5 mL) and 
benzenesulfonyl chloride (0.15 g, 0.83 mmol) was added to the suspension with vigorous 
stirring. Dioxane (5 mL) was added and the reaction mixture was heated at 37 °C overnight, 
and then allowed to cool to room temperature. The aqueous layer was extracted with EtOAc 
and the combined organic layers were dried with MgSO4, filtered, and the solvent was 
evaporated to afford the crude product, which was purified on a reverse phase flash silica 
column using an Isolera (Biotage) (SNAP C18 30 g column, 20 mL/min, A = H2O with 0.1% 
formic acid; B = CH3CN, 5%B 1CV, 5%B-95%B 12CV, 95%B 2CV) to give the desired 
product 4-bromo-2-(phenylsulfonamido)benzoic acid as a colorless powder. Yield: 8% (0.020 


















H NMR (d6-acetone, 400 MHz) δ 7.94-7.86 (m, 4H), 7.66-764 (m, 1H), 7.61-7.57 (m, 2H), 
7.30 (dd, J = 8.5 Hz, J = 1.9 Hz, 1H). 
13
C NMR (d6-acetone, 100 MHz) δ 169.9, 142.9, 140.2, 
134.4, 134.2, 130.3, 129.0, 128.0, 126.9, 121.9. LC-MS (ESI
-
) m/z 356.1 [M-H]
-
, retention 
time 2.16 min (92%). HRMS (ESI
-
) m/z (calcd C13H9BrNO4S [M-H]
-
 = 353.9435), obsd. 
353.9445. IR (neat, cm
-1
): 3171 (br), 1669, 1386, 1247, 1168. 
 
2-Bromo-5-(pyridine-3-sulfonamido)benzoic acid (6) 
 
5-Amino-2-bromobenzoic acid (0.20 g, 0.93 mmol) was suspended in H2O (4 mL) and 
pyridine-3-sulfonyl chloride (0.20 g, 1.13 mmol) was added to the suspension with vigorous 
stirring. 1,4-Dioxane (8 mL) was added and the reaction mixture was heated at 30 °C 
overnight, and then allowed to cool to room temperature. The aqueous layer was extracted 
with EtOAc and the combined organic layers were dried with MgSO4, filtered, and the 
solvent was evaporated to afford the crude product, which was purified on a reverse phase 
silica column using an Isolera (Biotage) (SNAP C18 30 g column, 20 mL/min, A = H2O with 
0.1% formic acid; B = CH3CN, 5%B 1CV, 5%B-40%B 4CV, 40%B 4CV, 40%B-65%B 
2.4CV, 65%B-95%B 1CV, 95%B 2CV) to give the desired product 2-bromo-5-(pyridine-3-
sulfonamido)benzoic acid as a colorless powder. Yield: 89% (0.29 g, 0.82 mmol). 
1
H NMR (d6-acetone, 400 MHz) δ 7.89-7.88 (m, 1H), 7.87-7.86 (m, 1H), 7.86-7.85 (m, 1H), 
7.81 (t, J = 1.6 Hz, 1H), 7.66-7.63 (m, 2H), 7.59-7.56 (m, 2H). 
13
C NMR (d6-acetone, 100 
MHz) δ 165.7, 140.7, 140.3, 134.5, 134.2, 130.2, 128.7, 127.9, 127.4, 123.0, 120.8. LC-MS 
(ESI
+
) m/z 356.0 [M-H]
-
, retention time 1.83 min (100%). HRMS (ESI
-
) m/z (calcd 
C13H9BrNO4S [M-H]
-
 = 353.9435), obsd. 353.9444. IR (neat, cm
-1
















2-Bromo-5-(phenylsulfonamido)benzoic acid (7) 
 
5-Amino-2-bromobenzoic acid (0.20 g, 0.93 mmol) was suspended in H2O (4 mL) and 
benzenesulfonyl chloride (0.20 g, 1.11 mmol) was added to the suspension with vigorous 
stirring. Dioxane (8 mL) was added and the reaction mixture was heated at 30 °C overnight, 
and then allowed to cool to room temperature. The aqueous layer was extracted with EtOAc 
and the combined organic layers were dried with MgSO4, filtered, and the solvent was 
evaporated to afford the crude product, which was purified on a reverse phase flash silica 
column using an Isolera (Biotage) (SNAP C18 30 g column, 20 mL/min, A = H2O with 0.1% 
formic acid; B = CH3CN, 5%B 1CV, 5%B-95%B 10CV, 95%B 3CV) to give the desired 
product 2-bromo-5-(phenylsulfonamido)benzoic acid as a colorless powder. Yield: 66% (0.22 
g, 0.62 mmol).  
1
H NMR (d6-acetone, 400 MHz) δ 9.32 (s, 1H), 7.85-7.83 (m, 2H), 7.73 (d, J = 2.7 Hz, 1H), 
7.65-7.60 (m, 2H), 7.58-7.54 (m, 1H), 7.32 (dd, J = 8.7 Hz, J = 2.7 Hz, 1H). 
13
C NMR (d6-
acetone, 100 MHz) δ 166.6, 140.4, 138.4, 135.9, 134.4, 134.1, 130.1, 127.9, 125.1, 123.7, 
116.5. LC-MS (ESI-) m/z 356.0 [M-H]
-





 = 353.9435), obsd. 353.9442. IR (neat, cm
-1
): 3151, 1695, 1473, 
1291, 1157. 
 
Methyl 3-bromo-4-(phenylsulfonamido)benzoate (8a)  
 
Methyl 4-amino-3-bromobenzoate (0.153 g, 0.665 mmol) was dissolved in pyridine (2 mL) 
and cooled to 0 °C using an ice bath. Benzenesulfonyl chloride (90 μL, 0.705 mmol) was 
added dropwise to the reaction and the mixture was stirred at 0 °C for 2 h. Ice was added and 
the product was extracted with EtOAc (2  10 mL). The combined organic layers were dried 



















flash silica column using an Isolera (Biotage) (SNAP KP-Sil 24 g column, 15 mL/min, A = 
petroleum ether B = EtOAc, 20%B 1CV, 20%B-51%B 7.6CV) to give the product methyl 3-
bromo-4-(phenylsulfonamido)benzoate as a colorless powder. Yield: 27% (0.067 g, 0.18 
mmol). 
1
H NMR (d6-DMSO, 400 MHz) δ 10.25 (s, 1H), 8.04 (d, J = 1.9 Hz, 1H), 7.85 (dd, J = 8.3 
Hz, J = 1.80 Hz, 1H), 7.78 (d, J = 7.4 Hz, 2H), 7.67 (t, J = 7.4 Hz, 1H), 7.58 (t, J = 7.7 Hz, 
2H), 7.39 (d, J = 8.3 Hz, 1H), 3.82 (s, 3H). 
13
C NMR (d6-DMSO, 100 MHz) δ 164.5, 140.1, 
139.6, 133.8, 133.3, 129.4, 129.2, 128.1, 126.7, 125.7, 118.0, 52.5. LC-MS (ESI
+
) m/z 270.0 
[M-H]
-
, retention time 2.11 min (100%). HRMS (ESI
+
) m/z (calcd C14H12BrN4O3S [M+H]
+
 = 
369.9749), obsd. 369.9749. IR (neat, cm
-1
): 3447, 3364, 3113 (br), 1726, 1651, 1616, 1559, 
1450, 1412. 
 
3-Bromo-4-(phenylsulfonamido)benzoic acid (8)  
 
Methyl 3-bromo-4-(phenylsulfonamido)benzoate (0.036 g, 0.096 mmol) was dissolved in 
ethanol (1 mL) and sodium hydroxide solution (2 M in H2O, 1 mL, 2 mmol) was added. The 
mixture was heated to 50 °C for 1 h. The solvent was removed in vacuo and H2O (10 mL) 
and DCM (10 mL) were added. The layers were separated and then the aqueous layer was 
acidified with hydrochloric acid solution (3 M) upon which a white precipitate formed. The 
product 3-bromo-4-(phenylsulfonamido)benzoic acid was collected by vacuum filtration as a 
colorless solid. Yield: 45% (0.016 g, 0.045 mmol).  
1
H NMR (d6-DMSO, 400 MHz) 13.23 (s, 1H), 10.20 (s, 1H), 8.04 (d, J = 1.9 Hz, 1H), 7.85 
(dd, J = 8.2 Hz, J = 1.9 Hz, 1H), 7.78 (d, J = 7.4 Hz, 2H), 7.67 (t, J = 7.4 Hz, 1H), 7.58 (t, J = 
7.7 Hz, 2H), 7.36 (d, J = 8.2 Hz, 1H). 
13
C NMR (d6-DMSO, 100 MHz) δ 165.8, 140.5, 139.5, 
134.21, 133.6, 129.7, 129.6, 127.0, 126.1, 118.4. LC-MS (ESI
+
) m/z 356.0 [M-H]
-
, retention 
time 1.76 min (100%). HRMS (ESI
+
) m/z (calcd C13H10BrNO4SNa [M+Na]
+
 = 377.9406), 
obsd. 377.9398. IR (neat, cm
-1













2-Methoxy-4-pyridin-3-amine (0.142 g, 1.14 mmol) was dissolved in pyridine (2 mL) and 
cooled to 0 °C using an ice bath. Benzenesulfonyl chloride (0.16 mL, 1.25 mmol) was added 
dropwise to the reaction and the mixture was stirred at 0 °C for 1 h. Ice was added and a 
brown precipitate formed. The product was isolated by vacuum filtration as a brown powder. 
Yield: 22% (0.066 g, 0.25 mmol).  
1
H NMR (d6-DMSO, 400 MHz) δ 9.83 (s, 1H), 7.92–7.90 (m, 1H), 7.73-7.71 (m, 2H), 7.64-
7.60 (m, 1H), 7.57-7.52 (m, 3H), 6.95-6.92 (m, 1H), 3.59 (s, 3H). 
13
C NMR (d6-DMSO, 100 





, retention time 1.72 min (100%). HRMS (ESI
+
) m/z (calcd C12H12N2O3S 
[M+Na]
+
 = 286.0383), obsd. 286.0376. IR (neat, cm
-1
): 3256, 1596, 1474, 1430. 
 
2-Bromo-5-(pyridine-3-sulfonamido)benzoic acid (10) 
 
5-Amino-2-bromobenzoic acid (0.20 g, 0.93 mmol) was suspended in H2O (4 mL) and 
pyridine-3-sulfonyl chloride (0.20 g, 1.13 mmol) was added to the suspension with vigorous 
stirring. Dioxane (8 mL) was added and the reaction mixture was heated at 30 °C overnight, 
and then allowed to cool to room temperature. The aqueous layer was extracted with EtOAc 
and the combined organic layers were dried with MgSO4, filtered, and the solvent was 
evaporated to afford the crude product, which was purified on a reverse phase flash silica 
column using an Isolera (Biotage) (SNAP C18 30 g column, 20 mL/min, A = H2O with 0.1% 
formic acid; B = CH3CN, 5%B 1CV, 5%B-40%B 4CV, 40%B 4CV, 40%B-65%B 2.4CV, 
65%B-95%B 1CV, 95%B 2CV) to give the desired product 2-bromo-5-(pyridine-3-






















H NMR (d6-acetone, 400 MHz) δ 8.96 (dd, J = 2.7 Hz, J = 0.8 Hz, 1H), 8.79 (dd, J = 4.8 Hz, 
J = 1.6 Hz, 1H), 8.17 (dq, J = 8.1 Hz, J = 1.6 Hz, J = 0.8 Hz, 1H), 7.74 (d, J = 2.7 Hz, 1H), 
7.65 (d, J = 8.6 Hz, 1H), 7.59 (qd, J = 8.8 Hz, 4.02 Hz, J = 2.6 Hz, 1H), 7.35 (dd, J = 8.6 Hz, 
J = 2.7 Hz, 1H). 
13
C NMR (d6-acetone, 100 MHz) δ 166.5, 154.7, 148.5, 137.7, 136.7, 136.1, 
135.7, 134.5, 125.6, 125.0, 124.1, 117.2. LC-MS (ESI
+
) m/z 359.0 [M+H]
+
, retention time 
1.53 min (100%). HRMS (ESI
-
) m/z (calcd C12H10BrN2O3S [M+H]
+
 = 356.9539), obsd. 
356,9537. IR (neat, cm
-1
): 3266, 1683, 1328, 1237, 1168. 
 
4-Bromo-2-(naphthalene-2-sulfonamido)benzoic acid (11) 
 
2-Amino-4-bromobenzoic acid (0.20 g, 0.93 mmol) was suspended in H2O (3 mL) and 
naphthalene-2-sulfonyl chloride (0.25 g, 1.10 mmol) was added to the suspension with 
vigorous stirring. Dioxane (7 mL) was and the reaction mixture was heated at 37 °C for 5 h, 
then left stirring at room temperature overnight. The aqueous layer was extracted with EtOAc 
and the combined organic layers were dried with MgSO4, filtered and the solvent was 
evaporated to afford the crude product, which was purified by reverse phase flash silica 
column using an Isolera (Biotage) (SNAP C18 30 g column, 20 mL/min, A = H2O (0.1% 
formic acid) B = CH3CN, 5%B 2CV, 5%B-95%B 12CV, 95%B 2CV) to give the desired 
product 4-bromo-2-(naphthalene-2-sulfonamido)benzoic acid as a colorless powder. Yield: 
9% (0.035 g, 0.090 mmol).  
1
H NMR (d6-acetone, 400 MHz) δ 8.61-8.60 (d, J = 1.8 Hz, 1H), 8.19-8.17 (m, 1H), 8.09 (d, 
J = 8.7 Hz, 1H), 8.03-8.00 (m, 1H), 7.94 (d, J = 1.9 Hz, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.84 
(dd, J = 8.7 Hz, J = 1.9 Hz, 1H), 7.78 (dd, J = 8.5 Hz, J = 1.9 Hz, 1H). 
13
C NMR (d6-acetone, 
100 MHz) δ 169.8, 142.7, 136.8, 136.0, 134.1, 133.0, 130.8, 130.3, 129.8, 129.4, 128.9, 
128.8, 127.0, 122.8, 121.9, 115.7. LC-MS (ESI
+
) m/z 406.0 [M-H]
-
, retention time 2.41 min 
(100%). HRMS (ESI
-
) m/z (calcd C17H12BrNO4SNa [M+Na]
+
 = 427.9568), obsd. 427.9562. 
IR (neat, cm
-1
): 1675, 1387, 1246, 1164. 
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